PMID: 11342196May 9, 2001Paper

Clinical trials of Herceptin(R) (trastuzumab)

European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)
J Baselga

Abstract

This report summarises the clinical efficacy and safety findings from clinical trials of the new anti-HER2 monoclonal antibody Herceptin(R) (trastuzumab). Data from pivotal trials indicate that trastuzumab is active when added to chemotherapy in patients with advanced metastatic breast cancer. In particular, the combination significantly prolonged the median time to disease progression, increased the overall response rate, increased the duration of response, and improved median survival time by approximately 25% compared with chemotherapy alone. Furthermore, trastuzumab is active as a single agent in women with HER2-positive metastatic breast cancer, inducing durable objective tumour responses. In total, 15% of patients who had received extensive prior treatment for metastatic disease had an objective response. The median duration of response was 9.1 months following administration of single-agent trastuzumab. Notably, 2% of patients were free of disease progression at 6 months. The safety profile of trastuzumab either given alone or in combination was favourable.

References

May 15, 1992·Proceedings of the National Academy of Sciences of the United States of America·P CarterH M Shepard
Sep 1, 1993·Cancer Immunology, Immunotherapy : CII·G D LewisH M Shepard
May 9, 2001·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·C VogelS J. Stewart

❮ Previous
Next ❯

Citations

Apr 2, 2013·Angiogenesis·E M ProkopiouJ J Walsh
Jul 10, 2008·Investigational New Drugs·Noor Al-DasooqiDorothy M Keefe
Nov 27, 2008·Journal of Mammary Gland Biology and Neoplasia·Quanri Jin, Francisco J Esteva
Aug 30, 2003·American Journal of Surgery·Julian A Kim
Jun 20, 2003·European Urology·Ivar BleumerPeter F A Mulders
Sep 16, 2003·Cancer Treatment Reviews·Roy S Herbst, Fadlo R Khuri
Sep 10, 2005·Nature Biotechnology·Gregory P Adams, Louis M Weiner
Jan 15, 2003·Annual Review of Medicine·Margaret von MehrenLouis M Weiner
Dec 23, 2003·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Z LatifJ M S Bartlett

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Invasive Carcinoma

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Breast Invasive Carcinoma (Keystone)

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Related Papers

Cancer Research and Treatment : Official Journal of Korean Cancer Association
Eundeok ChangChangsuk Kang
Journal of Huazhong University of Science and Technology. Medical Sciences = Hua Zhong Ke Ji Da Xue Xue Bao. Yi Xue Ying De Wen Ban = Huazhong Keji Daxue Xuebao. Yixue Yingdewen Ban
Yongguang JiangJunmin Liu
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
Joanne E MortimerAndrew A Raubitschek
© 2021 Meta ULC. All rights reserved